<DOC>
	<DOC>NCT01377909</DOC>
	<brief_summary>Objective: The goal is to improve peginterferon sensitivity in previous poor responders. "Sensitivity" here means the host's ability to kill more HCV. Design: Twenty poor responders to prior PIFN/RBV will be given 48 weeks of statin monotherapy. Veterans and civilians between the ages of 18 and 70 are eligible.</brief_summary>
	<brief_title>HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Hepatitis C positive by HCV RNA within 180 days. No antiHCV medicine within 30 days of screening decompensated liver disease severe cardiac disease (ejection fraction &lt; 20% or uncontrolled angina) unexplained muscle pain at time of screening pregnancy renal insufficiency (creatine clearance &lt; 50 ml/min)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>chronic hepatitis C, interferon</keyword>
</DOC>